Replies to post #24442 on RespireRx Pharmaceuticals Inc (RSPI)

[K-G]

Neuro,
It looks like you were right and I was wrong in their ability to complete the study - at least with enough margin with out more time and/or money. But, since they bought time and money with the workforce reduction, the question is, do they now have enough of both to finish the trial?

[enemem]

I'd rather they raise $2.5 M this way than via a PIPE. Unfortunately, the PIPE may still be coming.

Criticism of cor's management ignores the fact that the entire microcap sector was blindsided by the economic melt-down. Cor's current distress has everything to do with the once-in-a-generation melt-down we are experiencing. I don't think cor's management is any great shakes, but blaming them for the current disaster (which implies that it could have been foreseen and avoided) is intellectually dishonest.

The fact that ampakines may have reduced opioid-induced SA isn't all that surprising. If a hypnotic rather than an opiate can be paired with the ampakine to counteract the arousal effects, yet still prevent SA, there may be something to run with here.

My own position is that RD is as good an indication as we could hope for from a regulatory standpoint, and ampakines show robust efficacy. I want to see cor make this happen. If they can't, either because of ineptitude on their part, or lack of interest on the part of partners, then I very much doubt that they'll ever find a way to profitability. It's not another indication we need, it's a partnership.